EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age

Ian P Keary iD, Roberto Ravasio, John R Fullarton, Paolo Manzoni, Marcello Lanari, Bosco A Paes, Xavier Carbonell-Estrany, Eugenio Baraldi, Jean-Éric Tarride, Barry Rodgers-Gray iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0289828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Ian P Keary und 9 weiteren Autor:innen. Beteiligte Einrichtung: Violicom Medical Limited, Aldermaston, Berkshire, United Kingdom. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the last Italian cost-utility assessment of palivizumab in 2009, new data on the burden of respiratory syncytial virus (RSV) and an International Risk Scoring Tool (IRST) have become available. The objective of this study was to provide an up-to-date cost-utility assessment of palivizumab versus no prophylaxis for the prevention of severe RSV infection in otherwise healthy Italian infants born at 29–31 weeks’ gestational age (wGA) infants and those 32–35wGA infants categorized as either moderate- or high-risk of RSV-hospitalization (RSVH) by the IRST. A decision tree was constructed in which infants received palivizumab or no prophylaxis and then could experience: i) RSVH; ii) emergency room medically-attended RSV-infection (MARI); or, iii) remain uninfected/non-medically attended. RSVH cases that required intensive care unit admission could die (0.43%). Respiratory morbidity was considered in all surviving infants up to 18 years of age. Hospitalization rates were derived from Italian data combined with efficacy from the IMpact-RSV trial. Palivizumab costs were calculated from vial prices (50mg: €490.37 100mg: €814.34) and Italian birth statistics combined with a growth algorithm. A lifetime horizon and healthcare and societal costs were included. The incremental cost-utility ratio (ICUR) was €14814 per quality-adjusted life year (QALY) gained in the whole population (mean: €15430; probability of ICUR being

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanInfant, NewbornInfantHumansPalivizumabCost-Benefit AnalysisGestational AgeAntiviral AgentsInfant, PrematureAntibodies, Monoclonal, HumanizedRisk FactorsHospitalizationItaly

Substanzen

PalivizumabAntiviral AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Violicom Medical Limited, Aldermaston, Berkshire, United Kingdom.
  • MA Provider, Milan, Lombardy, Italy.
  • Department of Public Health and Pediatric Sciences, University of Torino School of Medicine, Turin, Piedmont, Italy.
  • Division of Paediatrics and Neonatology, Degli Infermi Hospital, Ponderano, Italy.
  • Paediatric Emergency Unit, IRCCS-Policlinico Ospedaliero-Universitario di Bologna, Bologna, Italy.
  • Department of Pediatrics (Neonatal Division), McMaster University, Hamilton, Ontario, Canada.

ORCID-Profile: Ian P Keary, Barry Rodgers-Gray

Förderung

  • AstraZeneca

Zitieren

APA

Keary, I. P., Ravasio, R., Fullarton, J. R., Manzoni, P., Lanari, M., Paes, B. A., Carbonell-Estrany, X., Baraldi, E., Tarride, J. É., & Rodgers-Gray, B. (2023). A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age. PLOS ONE. https://doi.org/10.1371/journal.pone.0289828

Vancouver

Keary IP, Ravasio R, Fullarton JR, Manzoni P, Lanari M, Paes BA, et al. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age. PLOS ONE. 2023. doi:10.1371/journal.pone.0289828

BibTeX
@article{Keary2023,
  author = {Keary, Ian P and Ravasio, Roberto and Fullarton, John R and Manzoni, Paolo and Lanari, Marcello and Paes, Bosco A and Carbonell-Estrany, Xavier and Baraldi, Eugenio and Tarride, Jean-Éric and Rodgers-Gray, Barry},
  title = {A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0289828}
}
Kostenlos starten →